EIF3B Associates with Exacerbated Clinical Features, Poor Treatment Response and Survival in Adult Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Patients.

Abstract

Objective: This study was undertaken to investigate eukaryotic translation initiation factor 3 subunit B (EIF3B) expression and its clinical value for indicating disease progression and prognosis in adult Philadelphia chromosome negative acute lymphoblastic leukemia (Ph- ALL) patients. Methods: Totally, 76 adult Ph- ALL patients and 30 healthy donors (HDs) were included. Bone marrow (BM) samples before therapy (baseline), after 4-week therapy of Ph- ALL patients and the BM samples of HDs were collected. Then, EIF3B expression in BM was detected by reverse transcription quantitative polymerase chain reaction. Results: EIF3B expression was increased in Ph- ALL patients compared with HDs, which distinguished Ph- ALL patients from HDs (area under the curve [AUC]: 0.928; 95% confidence interval [CI]: 0.882-0.974) by receiver operating characteristic curve. Furthermore, higher baseline EIF3B expression was associated with elevated white blood cell and bone marrow blasts, while it was associated with lower complete remission (CR) within 4 weeks and less allogeneic hematopoietic stem cell transplant achievements in Ph- ALL patients. Additionally, higher baseline EIF3B expression was associated with decreased disease-free survival but not overall survival. However, it was associated with raised 1-year mortality and 3-year mortality in Ph- ALL patients. After 4-week therapy, EIF3B expression was reduced in total Ph- ALL patients. Notably, the reduction of EIF3B expression was more obvious in Ph- ALL patients who achieved CR within 4 weeks compared with Ph- ALL patients who did not achieve CR within 4 weeks. Conclusion: EIF3B overexpression is related to worsened clinical features, poor treatment response and survival in adult Ph- ALL patients.

• Authors: Feiyue Zhu, Yesong Fu, Xiaojuan He
• Journal: Technology in cancer research & treatment (Technol Cancer Res Treat) 2021 Jan-Dec Vol. 20 Pg. 15330338211041464 ISSN: 1533-0338 [Electronic] United States
• PMID: 34617851 (Publication Type: Journal Article)

Chemical References

• Biomarkers
• EIF3B protein, human
• Eukaryotic Initiation Factor-3
• Vincristine
• RNA
• Cyclophosphamide
• Asparaginase
• Prednisone
• Daunorubicin

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Asparaginase (administration & dosage)
• Biomarkers (blood)
• Bone Marrow (metabolism, pathology)
• Case-Control Studies
• Cyclophosphamide (administration & dosage)
• Daunorubicin (administration & dosage)
• Disease Progression
• Disease-Free Survival
• Eukaryotic Initiation Factor-3 (genetics)
• Female
• Hematopoietic Stem Cell Transplantation
• Humans
• Leukocyte Count
• Male
• Philadelphia Chromosome
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (genetics, pathology, therapy)
• Prednisone (administration & dosage)
• RNA (metabolism)
• ROC Curve
• Survival Rate
• Treatment Outcome
• Vincristine (administration & dosage)
• Young Adult